{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:02:00Z","timestamp":1774868520241,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/fbp.0b013e32833e7efd","type":"journal-article","created":{"date-parts":[[2010,8,20]],"date-time":"2010-08-20T12:31:47Z","timestamp":1282307507000},"page":"654-659","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the effects of \u03b12 adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats"],"prefix":"10.1097","volume":"21","author":[{"given":"Sarah M.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Prus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210202","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R2-8-20210202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0773.1982.tb01032.x","article-title":"Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade","volume":"51","author":"Arnt","year":"1982","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"R3-8-20210202","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R4-8-20210202","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/BF00506193","article-title":"Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine","volume":"325","author":"Doxey","year":"1984","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R5-8-20210202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.286.5437.105","article-title":"Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade","volume":"286","author":"Hertel","year":"1999","journal-title":"Science"},{"key":"R6-8-20210202","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/sj.npp.1300119","article-title":"The [alpha]2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms","volume":"28","author":"Invernizzi","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R7-8-20210202","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(24)37196-4","article-title":"Discriminative stimulus effects of 8-hydroxy-2-(di-n-propylamino)tetralin in pigeons and rats: species similarities and differences","volume":"284","author":"Kleven","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"R8-8-20210202","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-004-1970-z","article-title":"Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation","volume":"177","author":"Kleven","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-8-20210202","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R10-8-20210202","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1037\/0735-7044.100.5.664","article-title":"Differential interactions of \u2018prosexual\u2019 drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors","volume":"100","author":"Kwong","year":"1986","journal-title":"Behav Neurosci"},{"key":"R11-8-20210202","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00004714-199308000-00006","article-title":"Idazoxan, an \u03b12 antagonist, augments fluphenazine in schizophrenic patients: a pilot study","volume":"13","author":"Litman","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"R12-8-20210202","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1192\/bjp.168.5.571","article-title":"Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine","volume":"168","author":"Litman","year":"1996","journal-title":"Br J Psychiatry"},{"key":"R13-8-20210202","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1017\/S1461145705005328","article-title":"Combined alpha2 and D2\/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat","volume":"8","author":"Marcus","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"R14-8-20210202","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr Bull"},{"key":"R15-8-20210202","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R16-8-20210202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X","article-title":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states","volume":"35","author":"Millan","year":"2000","journal-title":"Synapse"},{"key":"R17-8-20210202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjp.0701343","article-title":"Presynaptic imidazoline receptors and non-adrenoceptor [3H]-idazoxan binding sites in human cardiovascular tissues","volume":"122","author":"Molderings","year":"1997","journal-title":"Br J Pharmacol"},{"key":"R18-8-20210202","article-title":"Guide for laboratory animal facilities and care","year":"1996"},{"key":"R19-8-20210202","first-page":"539","article-title":"Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics","volume":"8","author":"Newman-Tancredi","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"R20-8-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s002130050124","article-title":"Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin","volume":"128","author":"Prinssen","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"R21-8-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ddr.20370","article-title":"The discriminative stimulus properties of idazoxan: mediation by both \u03b12 adrenoceptor antagonism and 5-HT1A receptor agonism","volume":"71","author":"Prus","year":"2010","journal-title":"Drug Dev Res"},{"key":"R22-8-20210202","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02245290","article-title":"Discriminative stimulus properties of 8-OH-DPAT: relationship to affinity for 5HT1A receptors","volume":"108","author":"Sanger","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"R23-8-20210202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-8-20210202","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications","volume":"178","author":"Toll","year":"1998","journal-title":"NIDA Res Monogr"},{"key":"R25-8-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1056-8719(97)00104-4","article-title":"A novel computer-controlled conditioned avoidance apparatus for rats","volume":"38","author":"Wadenberg","year":"1998","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R26-8-20210202","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0091-3057(00)00483-4","article-title":"Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats","volume":"68","author":"Wadenberg","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"key":"R27-8-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S1461145706006638","article-title":"Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence","volume":"10","author":"Wadenberg","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"R28-8-20210202","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-2999(97)01125-4","article-title":"Differentiation of 5-HT1A receptor ligands by drug discrimination","volume":"333","author":"Wolff","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"R29-8-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00008877-201010000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T20:59:45Z","timestamp":1740430785000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008877-201010000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0b013e32833e7efd","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}